C4 Therapeutics CCCC
NASDAQ CCCC
$2.89 -0.11 (-3.67%)
At close: Nov 11, 2026 · 4:00 PM EST

C4 Therapeutics (CCCC) Preferred Stock Liabilities (2019 - 2020)

Updated

C4 Therapeutics' Preferred Stock Liabilities was $256.52 million in Q3 2020, up 131.1% from $111 million a year earlier and up 1.8% from the prior quarter.

Analysis

C4 Therapeutics (CCCC) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends

At the end of FY2019, Preferred Stock Liabilities at C4 Therapeutics came in at $111 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 C4 Therapeutics 393.93 Mn -549.34 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2020 256.52 Mn
Jun 30, 2020 252.02 Mn
Dec 31, 2019 111.00 Mn
Sep 30, 2019 111.00 Mn
API Access

C4 Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=CCCC&period=max&api_key=YOUR_API_KEY